Completed
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
NCT00888004
- Conditions
- Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +12 more
- Locations
-
- Novartis Investigative Site Dresden, Germany
- Novartis Investigative Site Kassel, Germany
- Novartis Investigative Site Leun-Biskirchen, Germany
- Novartis Investigative Site Marburg, Germany